The BIA is the UK’s leading trade association for life sciences, and we have an award-winning policy and public affairs team. The work is varied, stimulating, and at times challenging. At the moment, we have two vacancies open in our policy and public affairs team; A Policy and Public Affairs Manager, and a Talent, People and Skills Manager.
A job description only tells part of the story, so we sat down with BIA Policy and Projects Manager, Dr. Martin Turner, and BIA Senior Policy and Public Affairs Executive, Eric Johnsson, to find out more about their roles and what working at the BIA is really like.
JP Morgan saw key M&A activity, new approaches from key UK pharma, a buzz about cell and gene therapy and concerns about the ongoing impact of the US Government shutdown. I’ve written a short blog on my perspective here.
On Brexit, the vote tomorrow is a key watershed, but for our sector we expect ongoing detail from the government on no-deal contingencies. We will focus our analytical and briefing capability on providing members with actionable information, in what is a very uncertain political context.
Key M&As set a positive tone for JPM 2019, as the sector shrugged off US stock market setbacks at the end of 2018. First out of the blocks were GSK taking Tesaro in a £3.8bn deal (announced before the conference) and since ringing in the new year we’ve seen Takeda complete their acquisition of Shire, Bristol-Myers Squibb acquire Celgene in a record breaking £70bn deal and Eli Lilly purchase Loxo Oncology for £6.24bn. These large pharma deals show desire for a strategic pipeline and prove the inherent value of biotech as a driver of innovation. More than half of new drugs registered in the coming years are expected to be made by small companies which large players may then look to add to their portfolio. The outlook for M&As looks strong and venture are keen to put money to work knowing the
CHAIN has just put out a press release regarding our recent runner-up placement in the EuropaBio Biotech SME Awards, where we won a two-year membership of EuropaBio. We would be very grateful if you could circulate among the BIA network.
The news was announced on our website today: https://chainbiotech.com/2019/01/09/chain-awarded-europabio-membership/
Kind regards & Happy New Year,
ELIXIR is an intergovernmental organisation that unites leading life science organisations in managing and safeguarding the increasing volume of data being generated. ELIXIR coordinates, integrates and sustains bioinformatics resources and services across its Nodes, and enables users in academia and industry to freely access services that are vital for their work.
A nationwide genomics initiative in Namibia will bring the benefits of precision medicine to the southern African republic. Global Gene Corp is collaborating with the University of Namibia as well as the Namibian Ministry of Higher Education, Training and Innovation to make this health milestone a reality.
With a Brexit deal signed between the EU and the UK at the weekend, we’ll be distributing our Brexit briefing on what it means for our sector to members tomorrow. We’ll follow that with our monthly Brexit webinar this Friday where myself and Laura Collister will put the deal in its political context, analyse the next stage of parliamentary ratification and endeavour to answer your questions.